https://www.selleckchem.com/products/BI-2536.html
The population consisted of 63.1% women and 72.6% were ≥65 years old. There were no appreciable differences in the incidence rates of MACE, AMI or stroke between users of mirabegron and antimuscarinics. Incidence rates of CV mortality (hazard ratio 0.83, 95% confidence interval 0.73-0.95) and all-cause mortality (hazard ratio 0.80, 95% confidence interval 0.76-0.84) were no higher with mirabegron vs antimuscarinics. Results restricted to episodes at high risk for CV events or stratified by age ( 65 years, ≥65 years) or prior overact
إعجاب
علق
شارك
